About this episode

The episode discusses the benefits and potential risks associated with GLP-1 inhibitors like Ozempic.

A new class of drugs, GLP-1 inhibitors (Ozempic being the most recognizable) has seemingly taken the world by storm. If the hype is to be believed, there seems to be enormous upsides and zero downsides to these new wonders of chemistry. Is that really the case, or might there be reason for caution? Join the Gwartney Institute for an insightful discussion on the promise and perils of these powerful peptides.

More episodes of Faith and Economics

• Humanomics at Creighton University with Drs. Koyama, Haeffele, Thomas | #390 · April 20, 2026 · 46 min
• Baseball, Literature, and Culture -Dr. Andy Hazucha | #389 · April 13, 2026 · 38 min
• Credit Score Clean-up with Chad McCullough | #388 · April 6, 2026 · 32 min
• Anarchotyranny | #387 · March 30, 2026 · 31 min
• Two Types of Authoritarianism | #386 · March 23, 2026 · 37 min
• The Bible as The DNA of Western Civilization | #384 · March 9, 2026 · 33 min

Explore listener stats, chart rankings, contacts and more on the Faith and Economics podcast page.